Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16849
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCross, Amanda J-
dc.contributor.authorGeorge, Johnson-
dc.contributor.authorWoodward, Michael C-
dc.contributor.authorAmes, David-
dc.contributor.authorBrodaty, Henry-
dc.contributor.authorWolfe, Rory-
dc.contributor.authorConnors, Michael H-
dc.contributor.authorElliott, Rohan A-
dc.date2017-09-01-
dc.date.accessioned2017-09-21T04:04:23Z-
dc.date.available2017-09-21T04:04:23Z-
dc.date.issued2017-
dc.identifier.citationJournal of Alzheimer's Disease 2017; 60(2): 349-358en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16849-
dc.description.abstractBackground:There is limited evidence regarding the association between potentially inappropriate medications (PIM) and mortality in older people with cognitive impairment. Objective:To examine whether use of medications considered to be potentially inappropriate in older people with cognitive impairment (PIMcog) and anticholinergic cognitive burden (ACB) were associated with mortality in people who attended memory clinics. Methods:Cross-sectional and longitudinal analyses of data from the Prospective Research In MEmory clinics (PRIME) study. Participants were community-dwelling people who attended nine memory clinics and had a diagnosis of mild cognitive impairment or dementia. PIMcog was defined as any medication considered potentially inappropriate for a person with cognitive impairment according to Beers or STOPP criteria. Anticholinergic burden was calculated using the ACB scale. Time-dependent Cox-proportional hazards regression was used to analyze associations between PIMcog use/ACB score and all-cause mortality over a three-year follow-up period. The regression model included the baseline variables: age, gender, education, cognitive diagnoses, total number of medications, disease-burden, cognition, physical function, and neuropsychiatric symptoms. Results:Of 964 participants, 360 (37.3%) used one or more PIMcog at some time during the study; most commonly anticholinergics and sedatives. 624 (64.7%) participants used a medication with potential or definite anticholinergic properties (ACB>0) at some point during the study. Both PIMcog use (adjusted hazard ratio: 1.42 95% CI: 1.12–1.80) and ACB score (adjusted hazard ratio: 1.18 95% CI: 1.06–1.32) were associated with mortality. Conclusion:Use of PIMcogs and medications with anticholinergic properties was common among memory clinic patients and both were associated with mortality.en_US
dc.subjectAlzheimer’s diseaseen_US
dc.subjectCholinergic antagonistsen_US
dc.subjectCognitive dysfunctionen_US
dc.subjectDementiaen_US
dc.subjectInappropriate prescribingen_US
dc.subjectMortalityen_US
dc.subjectPotentially inappropriate medication listen_US
dc.titlePotentially inappropriate medication, anticholinergic burden, and mortality in people attending memory clinicsen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJournal of Alzheimer's Diseaseen_US
dc.identifier.affiliationCentre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationMedical and Cognitive Research Unit, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationNational Ageing Research Institute, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationUniversity of Melbourne Academic Unit for Psychiatry of Old Age, St George’s Hospital, Kew, Victoria, Australiaen_US
dc.identifier.affiliationDementia Collaborative Research Centre, School of Psychiatry, UNSW Australia, Sydney, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Epidemiology and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationPharmacy Department, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/28869467en_US
dc.identifier.doi10.3233/JAD-170265en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherElliott, Rohan A
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptPharmacy-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

66
checked on Mar 9, 2025

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.